Logo
x

Search

Subscribe Now

Bridge Biotherapeutics

Bridge Biotherapeutics Reports P-IIa Clinical Trial Results of BBT-401 for the Treatment of Ulcerative Colitis

Bridge Biotherapeutics Reports P-IIa Clinical Trial Results of BBT-401 for the Treatment of Ulcerative Colitis

  • February 21, 2023
Top 20 Biopharma Deal Terminations of 2020 Based on Total Deal Value

Top 20 Biopharma Deal Terminations of 2020 Based on Total Deal Value

  • February 11, 2021
Boehringer Ingelheim Signs a Worldwide License Agreement with Bridge Biotherapeutics for its BBT-877 for $1.28B

Boehringer Ingelheim Signs a Worldwide License Agreement with Bridge Biotherapeutics for its BBT-877 for $1.28B

  • July 19, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.